

## CANCER CACHEXIA

- “ A wasting syndrome characterized by loss of muscle and fat caused by an aberrant host response to a wide variety of chronic illnesses. Anorexia usually accompanies cachexia, and is caused by related mediators acting upon the hypothalamus.”

*MacDonald et al  
JACS, July 2003*

## Cancer Cachexia - Anorexia



## Negativity – cancer nutrition

- Lack of past success
  - alimentionation trials
  - counselling
  - therapeutic failures (cyproheptadine, pentoxifylline, hydrazine)
- Qualified success
  - (corticosteroids, megestrol)

## Negativity – cancer nutrition

- False Dichotomy

Tumour Growth vs Symptom Control

- Skewed Research

## Do we think it's important?

- ASCO 2005 - 4119 presentations
- Nutrition - 15
- Gemcitabine - 106

## ASCO STATEMENT JCO16: MAY 1998

- “ONCOLOGISTS MUST LEARN TO RECOGNIZE AND RESPOND TO THAT TRANSITION POINT IN A PATIENT'S CARE WHEN DISEASE ORIENTED ANTICANCER THERAPY MUST GIVE WAY TO SYMPTOM ORIENTED PALLIATIVE THERAPY”

## Canadian Institutes of Health Research Cancer Institute

Palliative care aims to improve the life of patients and families through early identification and impeccable management of suffering associated with cancer, and emphasis on the positive aspects of life inclusive of physical, psychosocial and spiritual sources. Palliative care is an exercise in prevention — prevention of suffering through prioritizing the diagnosis and skillful care of sources of distress throughout the course of cancer and for the family during the bereavement period. It is not simply an end of life concept separate from other aspects of cancer research and control.

## Cancer Cachexia - Anorexia



## Anorexia-cachexia

### PERIPHERAL

### CENTRAL

- Inflammation
  - cytokines, eicosanoids
- Hypercatabolism
  - dysautonomia
- Hypogonadism
- Oxidative Stress
- Genetic Predisposition
- Tumour Factors

Hypothalamus


Cerebral influence

appetite

## PROTEOLYSIS INDUCING FACTOR

- Glycoprotein
- Induces proteolysis, not anorexia
- Does not cause anorexia
- Present in : serum — MAC 16 mice  
urine — cancer patients with weight loss
- Activates Prostaglandin  $E_2$
- Attenuated by EPA (omega-3 fatty acid)

(Tisdale)



## Advancing Cancers

Infiltrating →

TAM

TIL

Growth Factors  
Angiogenesis  
Proteases – matrix

↓ Tumour Immunity  
Th2 ↑ Th1 ↓

We suggest that the inflammatory cells and cytokines found in tumours are more likely to contribute to tumour growth, progression and immunosuppression than they are to mount an effective host anti-tumour response... some types of inflammation may provide 'the fuel that feeds the flames'.

Balkwill, Mantovani. *Lancet*. February 17, 2001


## Metabolic Changes in Tumor Related Weight Loss

- **↑Anaerobic Glycolysis**
- **Insulin Resistance**
- **Diminished Lipogenesis**
- **Lipolysis**
- **Protein Catabolism**
- **Decreased Muscle Protein Synthesis**
- **↑Acute Phase Protein Response - CRP**
- **↑Pro-Inflammatory Cytokines**

## 'A Wound That Doesn't Heal'

- **Wound Infection**
  - Organise cellular response
  - Suppress when resolved
- **Tumours**
  - Organise cellular response
  - Suppression cues lost
  - Chronic Inflammation
    - Support tumour growth
      - ✓ Growth factors
      - ✓ Angiogenesis
      - ✓ Symptoms – cachexia

Balkwill, Lin, others



## Lung Cancer – 1<sup>ST</sup> Presentation

- **C-reactive Protein** – 80 ↑
- **Survival** -- < 10 mgm/L -- 11 months (median) -- >100mgm/L -- 3 months
- **Correlations** -- weight loss, fatigue, poor performance status, ↓ albumin and hemoglobin

Scott et al. *BCJ* 2002 87-264

## Cancer Inflammation - Chemotherapy


### Pharmacokinetics

- ↓ cytochrome P450
- docetaxel, vinorelbine





### Pharmacodynamics

- Acute phase proteins
- ↑ binding?
- Cytokines
  - receptor interference?
  - 2<sup>nd</sup> messenger interference? (platinum, interleukin 2)

Slaviero et al *Lancet Oncology* April 2003 224







Upon this gifted age, in its dark hour,  
Rains from the sky a meteoric shower  
Of facts...they lie unquestioned, uncombined.  
Wisdom enough to leech us of our ill  
Is daily spun, but there exists no loom  
To weave it into fabric.

*Edna St Vincent Millay*

**WHO Definition Palliative Care — 2002**

Palliative care is an approach which improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual.

## Cachexia – Early Rx

Informed Opinion

Clinical Trials

Time from diagnosis

Appetite loss

Correlation

Inflammation

Cachexia

Cachexia

Early – Atrophy – fibres intact

Late - Apoptosis – fibres disappear

## CANCER NUTRITION – REHABILITATION PROGRAMME

### ■ Objectives

- To provide an assessment and therapeutic clinical programme for patients with cancer and early identified anorexia-cachexia, fatigue and functional loss.
- To create a centre of excellence for the conduct of research on cancer induced anorexia-cachexia and fatigue.



## Basic Assessment Package

### ■ Paper and Pencil

- PG-SGA
- ESAS

### ■ Blood

- C-reactive protein
- Testosterone

### ■ Diet History

- Detail Problems
  - Depression
  - Constipation

## Screen – Referral - CNR

- Albumin < 35gm/L
- CRP > 50
- Weight Loss > 5% in 6 months
- Fatigue > 6 ESAS
- Anorexia > judgment
- Function > judgment

## Mechanisms of secondary cachexia

### ■ Impaired oral intake

- cognitive impairment, delirium
- depression, fatigue
- pain, dyspnoea, other uncontrolled symptoms
- stomatitis, taste alteration
- dry mouth
- dysphagia, odynophagia
- gastric stasis
- bowel obstruction
- nausea & Vomiting
- severe constipation



## Anorexia-cachexia general approach

1. Correct other symptoms  
mouth care, anxiety, pain, constipation
2. Gastric Atony  
prokinetics
3. Review patient – family goals
4. Nutritional counselling  
dietitian, print dietary guide, internet

## Muscles Need

- Blood Supply
  - oxygen ..... Anemia
  - nutrients ..... Amino acid delivery
- Energy Supply ... ATP Hypercatabolism
- Protein Synthesis ... Anabolic factors
- Balanced Proteolysis ... Ubiquitin ligases
- Exercise ..... Inanition Spiral
- Neuromuscular Junction .... ???

## General Pharmacotherapy

### ➤MUSCLE

- Amino Acids
- Omega 3's
- Vitamins (C, E, B, zinc)

### ■ APPETITE STIMULATION

- Megestrol – corticosteroids  
short-term

## Eicosapentaenoic acid (EPA)



- EPA, an omega-3 polyunsaturated fatty acid found in deep sea oily fish (e.g. salmon, sardines, tuna, mackerel), has been shown to:

- ↓ pro-inflammatory cytokine production<sup>1</sup> ↓ level/activity of proteolysis-inducing factor<sup>2</sup>
- possess anti-cachectic properties<sup>3</sup>
- slow tumour growth<sup>3</sup>
- increase survival


EPA in combination with protein and calories may counteract the causes of cancer cachexia resulting in weight gain and (partial) restoration of body mass

## NCI – SC18 megestrol vs EPA

### ■ End Points

	<u>meg</u>	<u>comb</u>	<u>EPA</u>
10% weight gain	18%	11%	6%
Appetite	NS (range 40% - 69%)		
Survival	NS		
Life Quality	NS		

Jatoi et al. JCO;22(12):2469-76



## General Pharmacotherapy

### ➤ MUSCLE

- ❑ Amino Acids
- ❑ Omega 3's
- ❑ Vitamins (C, E, B, zinc)

### ■ APPETITE STIMULATION

- ❑ Megestrol – corticosteroids short-term

## Rehabilitation - Exercise


- Reduce cancer incidence
- Increase NK activity
- Increase QOL and fitness, decrease fatigue
- Geriatric literature
  - Clear consensus – increased function
- Fatigue therapy

## Exercise – patient motivation


1. Personal Control --Empowerment
2. Do 'something normal'
3. Belief – exercise helps response toxicity

ASCO – Roubenoff & Tattersall 2002

## Weight stabilization in patients who reported loss at baseline



## Change in the QoL from the baseline in those who reported poor ( $\geq 5$ ) QoL at the baseline




$P < 0.05$  (Wilcoxon Signed Rank test) when compared to baseline



## Levels of Training (112 patients)

- 43% trained at a high level  
2-3 X per wk, progressive cardiovascular & resistance exercises
- 10% trained at a moderate level  
1-2 X per wk, low level cardiovascular & resistance exercises
- 47% trained at a low level  
1-2 times per month, home care, theraband.

## Functional Improvement in pts with High Level of Training



## Progressive Training Limitations

- Cardiovascular: 93%  
High resting HR  
Low HR reserves  
Autonomic insufficiency
- Neurological symptoms: 3%
- Dyspnea: 2%
- Bone metastases: 2%

## Research on CAA: McGill Studies Completed – Ongoing - In Planning

- Identification of some causative factors
  - Translational Research at McGill Cancer Centre
- Potential benefit of muscle sustaining therapies
  - Omega-3 fatty acids *Study completed*
  - ACE Inhibitors *Study inaugurated June 2003*
  - Amino Acids *Ongoing*
  - Creatine *NCI(C) – Mayo NCCTG - fall*
- Role of Exercise-Rehabilitation
- NET Grant – PI V Baracos Univ of Alberta

## Potential Clinical Trials

- Cardioactive agents – ACE inhibitors
- Beta 2 agonists
- Cytokine inhibitors
- Ghrelin
- Hypothalamic mediators – MC4 antagonists
- Myostatin inhibitors

## Logical pragmatic trial

Amino Acid		Amino Acid
Anabolic Agent	vs	Anti-inflammatory
Anti-inflammatory		Anabolic Agent
? COX 2		
EPA		
Role of Exercise		



## New Platform Considerations

- Address Hypogonadism
- Creatine Study
- NSAIDS
- Control Anemia

## Cachexia – Developing Countries

- Specific Counselling (print)
- Vitamins
- Amino Acids
- Omega 3's
- Exercise

